Characterisation of cysteamine prodrugs for the treatment of cystinosis and evaluation of liquid fill technology.

Cystinosis is a rare, autosomal, recessive disease characterised by raised levels of the amino acid cystine in the cells of most organs in the body which can cause organ damage. The treatment involves the oral administration of the aminothiol, cysteamine (Cystagon(TM)), but this has an offensive taste and smell, can cause vomiting and its metabolites are excreted from the body via breath (halitosis) and sweat, which can cause poor patient compliance. The main research aim was to characterise two cysteamine prodrugs for the treatment of cystinosis and evaluate the suitability of liquid fill technology using prodrugs, or alternative drug models, to determine excipient usage using solubility, stability and capsule shell compatibility data to potentially develop prototype formulations based on liquid fill technology.

Name dc:type.qualificationname

MRes

Level dc:type.qualificationlevel

Masters

Grantor dc:publisher.institution

Robert Gordon University

Year dc:date.issued

2016

Author dc:creator

• McCormick, John James

• Cystinosis
• Formulation
• Capsules
• Encapsulation
• Modified release
• Gelucire
• Liquid fill technology

Language dc:language

en

Identifier

oai:rgu-repository.worktribe.com:248877

OAI identifier oai:identifier

oai:rgu-repository.worktribe.com:248877